IDEAYA BIOSCIENCES INC (IDYA) Stock Analyst Ratings
USA - NASDAQ:IDYA - US45166A1025 - Common Stock
30.48 USD
-0.88 (-2.81%)
30.2 USD
-0.28 (-0.92%)
ChartMill assigns a Buy % Consensus number of 85% to IDYA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 48.71. This target is 59.79% above the current price.
IDYA was analyzed by 25 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IDYA.
In the previous month the buy percentage consensus was at a similar level.
IDYA was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-23 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-18 | Guggenheim | Initiate | Buy |
| 2025-09-12 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-09-09 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-09-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-04 | JMP Securities | Initiate | Market Outperform |
| 2025-09-04 | Barclays | Initiate | Overweight |
| 2025-09-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-28 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-22 | TD Cowen | Initiate | Buy |
| 2025-07-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-26 | Wells Fargo | Initiate | Overweight |
| 2025-05-22 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-14 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-13 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-11-18 | Stephens & Co. | Initiate | Overweight |
| 2024-11-05 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-10-29 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-10-24 | UBS | Initiate | Buy |
| 2024-09-24 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-09-24 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-09-10 | Stifel | Maintains | Buy -> Buy |
IDEAYA BIOSCIENCES INC / IDYA FAQ
What is the price target for IDYA stock?
25 analysts have analysed IDYA and the average price target is 48.71 USD. This implies a price increase of 59.79% is expected in the next year compared to the current price of 30.48.
What is the consensus rating for IDEAYA BIOSCIENCES INC (IDYA) stock?
The consensus rating for IDEAYA BIOSCIENCES INC (IDYA) is 84.8 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover IDEAYA BIOSCIENCES INC (IDYA) stock?
The number of analysts covering IDEAYA BIOSCIENCES INC (IDYA) is 25.